U.S. Markets closed
  • S&P 500

    3,744.52
    -38.76 (-1.02%)
     
  • Dow 30

    29,926.94
    -346.93 (-1.15%)
     
  • Nasdaq

    11,073.31
    -75.33 (-0.68%)
     
  • Russell 2000

    1,752.51
    -10.18 (-0.58%)
     
  • Crude Oil

    88.96
    +0.51 (+0.58%)
     
  • Gold

    1,720.90
    +0.10 (+0.01%)
     
  • Silver

    20.69
    +0.03 (+0.15%)
     
  • EUR/USD

    0.9796
    -0.0190 (-1.9005%)
     
  • 10-Yr Bond

    3.8260
    +0.0670 (+1.78%)
     
  • Vix

    30.52
    +1.97 (+6.90%)
     
  • GBP/USD

    1.1171
    -0.0304 (-2.6453%)
     
  • USD/JPY

    145.0080
    +0.8090 (+0.5610%)
     
  • BTC-USD

    20,039.17
    -126.24 (-0.63%)
     
  • CMC Crypto 200

    456.11
    -7.01 (-1.51%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,311.30
    +190.77 (+0.70%)
     

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

·1 min read

WILMINGTON, Mass., September 08, 2022--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences in New York, including:

  • Baird 2022 Global Healthcare Conference on Tuesday, September 13th, at 10:15 a.m. EDT; and

  • Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, at 10:00 a.m. EDT.

Management will present an overview of Charles River’s strategic focus and business developments.

A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for approximately two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005134/en/

Contacts

Investor Relations:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com